General Biologicals Corporation (TPEX:4117)
Taiwan
· Delayed Price · Currency is TWD 4.150
0.00 (0.00%)
Mar 12, 2026, 2:59 PM CST
General Biologicals Revenue
General Biologicals had revenue of 110.73M TWD in the half year ending June 30, 2025, a decrease of -17.18%. This brings the company's revenue in the last twelve months to 251.38M, up 3.70% year-over-year. In the year 2024, General Biologicals had annual revenue of 251.93M, down -4.87%.
Revenue (ttm)
251.38M
Revenue Growth
+3.70%
P/S Ratio
1.00
Revenue / Employee
3.10M
Employees
81
Market Cap
252.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 251.93M | -12.90M | -4.87% |
| Dec 31, 2023 | 264.83M | -105.63M | -28.51% |
| Dec 31, 2022 | 370.46M | -181.20M | -32.85% |
| Dec 31, 2021 | 551.66M | 75.79M | 15.93% |
| Dec 31, 2020 | 475.87M | 236.22M | 98.57% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UniPharma | 88.44M |
| Golden Biotechnology | 44.58M |
| Bioray Biotech | 230.06M |
| Original BioMedicals | 381.00K |
| Mediera | 229.85M |
| Prince Pharmaceutical | 1.06B |
| Anxo Pharmaceutical | 883.22M |
| Excelsior Biopharma | 898.26M |